© 2020 MJH Life Sciences and AJMC. All rights reserved.
© 2020 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
September 26, 2020
Kassandra Munger, ScD, of the Harvard TH Chan School of Public Health, discusses findings that vitamin D deficiencies are linked to a greater risk of multiple sclerosis.
The biggest difference between ocrelizumab and the recently approved ofatumumab is that ofatumumab can be taken at home for relapsing forms of multiple sclerosis (MS), explained Patricia K. Coyle, MD.
Researchers hope that a more targeted retinoid acid X receptor compound could repair myelin without the adverse effects seen in every patient in this trial, which tested an already approved cancer drug.
September 24, 2020
Disease-modifying therapies (DMTs) are primarily effective through immunomodulation, in that they target relapse prevention, said Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, at Mayo Clinic.
September 14, 2020
Obesity is common in the general population and research has shown it can increase the risk of multiple sclerosis (MS), as well as increase diagnostic delays, explained Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba.
Nurses often get involved with patients with multiple sclerosis (MS) before their diagnosis and then work to educate them on the disease and its care, said Amy Perrin Ross, APN, MSN, CNRN, MSCN, Neuroscience Program Coordinator at Loyola University Medical Center.
To the extent that some factors are modifiable, the takeaway for clinicians is to encourage their patients with multiple sclerosis (MS) to adopt healthy habits.
September 13, 2020
The drug, mastinib, reduced the chance of a confirmed disability progression by 37% in phase 2b/3 study results.
With more multiple sclerosis (MS) treatments becoming available, it is now possible to better personalize approaches, explained speakers during a session at MSVirtual 2020: 8th Joint ACTRIMS-ECTRIMS Meeting.
It is well known that women are disproportionately affected by multiple sclerosis (MS), but there remains a lack of understanding regarding gender differences in response to treatments for MS, said Riley Bove, MD, assistant professor of neurology at the UCSF Weill Institute for Neurosciences.